1. Home
  2. EQ vs TNON Comparison

EQ vs TNON Comparison

Compare EQ & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • TNON
  • Stock Information
  • Founded
  • EQ 2017
  • TNON 2012
  • Country
  • EQ United States
  • TNON United States
  • Employees
  • EQ N/A
  • TNON N/A
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • TNON Medical Specialities
  • Sector
  • EQ Health Care
  • TNON Health Care
  • Exchange
  • EQ Nasdaq
  • TNON Nasdaq
  • Market Cap
  • EQ 13.1M
  • TNON 10.6M
  • IPO Year
  • EQ 2018
  • TNON 2022
  • Fundamental
  • Price
  • EQ $0.93
  • TNON $1.47
  • Analyst Decision
  • EQ Buy
  • TNON Strong Buy
  • Analyst Count
  • EQ 3
  • TNON 3
  • Target Price
  • EQ $3.00
  • TNON $11.67
  • AVG Volume (30 Days)
  • EQ 21.2M
  • TNON 13.4M
  • Earning Date
  • EQ 08-19-2025
  • TNON 08-13-2025
  • Dividend Yield
  • EQ N/A
  • TNON N/A
  • EPS Growth
  • EQ N/A
  • TNON N/A
  • EPS
  • EQ N/A
  • TNON N/A
  • Revenue
  • EQ $30,406,000.00
  • TNON $3,284,000.00
  • Revenue This Year
  • EQ N/A
  • TNON $39.03
  • Revenue Next Year
  • EQ N/A
  • TNON $66.24
  • P/E Ratio
  • EQ N/A
  • TNON N/A
  • Revenue Growth
  • EQ N/A
  • TNON 2.18
  • 52 Week Low
  • EQ $0.27
  • TNON $0.85
  • 52 Week High
  • EQ $1.50
  • TNON $15.79
  • Technical
  • Relative Strength Index (RSI)
  • EQ 71.79
  • TNON 70.15
  • Support Level
  • EQ $0.46
  • TNON $1.30
  • Resistance Level
  • EQ $1.25
  • TNON $1.63
  • Average True Range (ATR)
  • EQ 0.20
  • TNON 0.20
  • MACD
  • EQ 0.04
  • TNON 0.03
  • Stochastic Oscillator
  • EQ 57.41
  • TNON 33.11

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

Share on Social Networks: